Abstract 174P
Background
Hepatocellular carcinoma (HCC) patients with major vascular invasion (MVI) were generally recommend systemic treatment by guidelines, while some data showed R0 resection can improve survival than local treatment. Conversion therapy using immune checkpoint inhibitors may benefit these patients in the context of cancer immunotherapy. Here we report a prospective real-world study of PD-1 inhibitors in combination with tyrosine kinase inhibitors (TKIs) as a conversion therapy for HCC with MVI.
Methods
Briefly, the main inclusion criteria of the study (ChiCTR1900023914) was: Aged 18 to 75 years HCC patients diagnosed pathologically and/or radiologically, with at least one measurable lesion (mRECIST) and MVI. The criteria for Successful Conversion: 1. Child-Pugh score < 7. 2. ECOG PS score ≤1. 3. No extrahepatic lesion. 4. Intact vascular structure of the reserved liver and sufficient FLR.
Results
70 Patients were screened, and 39 patients enrolled in the study by May 20, 2020. Among them 35 patient accepted the combination therapy (Primary HCC n=31, Recurrence after local treatment n=4), in which 30 patients with PVTT, 2 with venous tumor thrombi and 3 with both. A total of 33 patients were assessable. The response evaluation according to mRECIST standard was in table below. Successful conversion rate based on radiology was 42.4% (14/33). Table: 174P
Summary of response evaluation and conversion rate
Best objective response, n | Total, n | ||||
CR n=5 | PR n=10 | SD n=12 | PD n=6 | 33 | |
Successful Conversion, n | 5 | 7 | 1 | 1 | 14 |
Reasons for not conversion | Inadequate FLR n=2, Poor CTP n=1 | Inadequate FLR n=11 | Inadequate FLR n=5 | ||
Patients underwent subsequent surgery, n | 4 | 3 | 1 | 1 | 9 |
Pathological evaluation of response | pPR: 1/4 | pPD: 2/3 | pSD | pPD |
The subsequent salvage surgery was all en-bloc R0 resection of both tumor and PVTT. No complications beyond Clavien-Dindo level III or postoperative mortality were observed. The median follow-up time was 7.2 months. The median relapse free survival and median overall survival was 3.9 months and 6.5 months respectively. Patients with pPD had a worse prognosis.
Conclusions
The combination therapy of PD-1 inhibitors and TKIs can be reviewed as a reasonable and promising conversion therapy option for advanced HCC with safety and effectiveness. Furthermore, pathology can confirm the response evaluation and guide subsequent treatment more precisely.
Clinical trial identification
ChiCTR1900023914.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
420TiP - UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib
Presenter: Satoru Miura
Session: e-Poster Display Session
443TiP - A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)
Presenter: Nathalie Gaspar
Session: e-Poster Display Session
7P - Machine learning intratumoral and axillary lymph node magnetic resonance imaging radiomics for predicting axillary lymph node metastasis in patients with early-stage invasive breast cancer (RBC-01 Study)
Presenter: Yujie Tan
Session: e-Poster Display Session
8P - Knowledge, practice and attitudes of physicians in low- and middle-income countries (LMIC) on fertility and pregnancy-related issues in young breast cancer patients
Presenter: Shah Zeb Khan
Session: e-Poster Display Session
9P - Survival status of elderly women with HR+ early breast cancer: An analysis of SEER database
Presenter: Wang Hao
Session: e-Poster Display Session
10P - Neoadjuvant immunotherapy plus chemotherapy in early triple-negative breast cancer: A meta-analysis of randomized controlled trials
Presenter: Jessa Gilda Pandy
Session: e-Poster Display Session
11P - Genetically predicted bipolar disorder is causally associated with increased risk of breast cancer: A Mendelian randomization analysis
Presenter: Haoxin Peng
Session: e-Poster Display Session
12P - Stromal tumour-infiltrating lymphocytes in human epidermal growth factor receptor 2-overexpressing breast cancer: Association with negative nodal metastasis
Presenter: Ren Xiaoqiu
Session: e-Poster Display Session
13P - A retrospective observational study on neoadjuvant chemotherapy in older adults based on the Joint Breast Cancer Registry Singapore
Presenter: Johan Chan
Session: e-Poster Display Session